ID   ES-2
AC   CVCL_3509
SY   ES2
DR   BTO; BTO:0004424
DR   CLO; CLO_0002947
DR   EFO; EFO_0002177
DR   AddexBio; C0017006/4971
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1978
DR   BCRC; 60067
DR   BCRJ; 0080
DR   BioGRID_ORCS_Cell_line; 435
DR   BioSample; SAMN02800400
DR   BioSample; SAMN03472439
DR   BioSample; SAMN10988319
DR   cancercelllines; CVCL_3509
DR   CCRID; 1101HUM-PUMC000371
DR   CCRID; 3101HUMTCHu111
DR   CCRID; 4201HUM-CCTCC00322
DR   CCTCC; GDC0322
DR   Cell_Model_Passport; SIDM00861
DR   CGH-DB; 323-2
DR   CLS; 305038
DR   Cosmic; 844353
DR   Cosmic; 897429
DR   Cosmic; 1044235
DR   Cosmic; 1102814
DR   Cosmic; 1113277
DR   Cosmic; 1139225
DR   Cosmic; 1223312
DR   Cosmic; 1305327
DR   Cosmic; 1312191
DR   Cosmic; 1328071
DR   Cosmic; 1450145
DR   Cosmic; 1708382
DR   Cosmic; 1709256
DR   Cosmic; 1995396
DR   Cosmic; 2074240
DR   Cosmic-CLP; 1240128
DR   DepMap; ACH-000906
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 1240128
DR   GEO; GSM95455
DR   GEO; GSM274699
DR   GEO; GSM313713
DR   GEO; GSM383926
DR   GEO; GSM416675
DR   GEO; GSM659376
DR   GEO; GSM784563
DR   GEO; GSM887008
DR   GEO; GSM888077
DR   GEO; GSM1001491
DR   GEO; GSM1176276
DR   GEO; GSM1291140
DR   GEO; GSM1340580
DR   GEO; GSM1341129
DR   GEO; GSM1669769
DR   GEO; GSM2474975
DR   IARC_TP53; 28314
DR   IGRhCellID; ES2
DR   LiGeA; CCLE_094
DR   LINCS_LDP; LCL-1806
DR   PharmacoDB; ES2_337_2019
DR   PRIDE; PXD000901
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_3509
DR   Wikidata; Q54832435
RX   DOI=10.26502/ogr072;
RX   PubMed=1717140;
RX   PubMed=9698466;
RX   PubMed=11103784;
RX   PubMed=12960427;
RX   PubMed=16382445;
RX   PubMed=17671176;
RX   PubMed=18560578;
RX   PubMed=18720132;
RX   PubMed=20081105;
RX   PubMed=20204287;
RX   PubMed=20215515;
RX   PubMed=22328975;
RX   PubMed=22460905;
RX   PubMed=22705003;
RX   PubMed=22710073;
RX   PubMed=23415752;
RX   PubMed=23839242;
RX   PubMed=24023729;
RX   PubMed=25049276;
RX   PubMed=25230021;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26388441;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=28273451;
RX   PubMed=30485824;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=35839778;
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/e/cell-lines-detail-457.html
WW   https://tcpaportal.org/mclp/
CC   Problematic cell line: Probably misclassified. It is dubious that this cell line originates from an African American 47 year old patient diagnosed with an ovarian clear cell adenocarcinoma. Immunohistochemical and qPCR analysis as well as its mutational profile support an ovarian serous adenocarcinoma origin (PubMed=25049276; DOI=10.26502/ogr072). Furthermore its genome ancestry clearly shows a Caucasian/European decent (PubMed=30894373) which is confirmed by mtDNA haplotyping (DOI=10.26502/ogr072).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: OCCP ovarian cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 31.11 hours (GrayJW panel); ~24 hours (ATCC=CRL-1978).
CC   HLA typing: A*03:01,68:02; B*14:02,41:01; C*07:01,08:02; DRB1*01:02,13:07 (PubMed=25960936).
CC   HLA typing: A*03:01,68:02; B*14:02,41:01; C*07:01,08:04; DQA1*04:01,04:01; DRB1*01:02,13:05' (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22705003; PubMed=25230021; PubMed=28273451; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 26144; PALB2; Simple; p.Lys295_Met296insTer (c.886delA) (p.Met296Terfs); ClinVar=VCV000143979; Zygosity=Unspecified (PubMed=25230021).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Homozygous (PubMed=20204287; PubMed=24023729; PubMed=25230021; PubMed=28273451; Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative phosphoproteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Secretome proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Transcriptome analysis by serial analysis of gene expression (SAGE).
CC   Genome ancestry: African=2.57%; Native American=0%; East Asian, North=3.68%; East Asian, South=0.75%; South Asian=7.03%; European, North=27.14%; European, South=58.83% (PubMed=30894373).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): AddexBio; ATCC; Cosmic-CLP; PubMed=22710073; PubMed=25230021; PubMed=25877200; PubMed=30485824
ST   Amelogenin: X
ST   CSF1PO: 10,15
ST   D13S317: 11
ST   D16S539: 11,13
ST   D18S51: 13,15
ST   D19S433: 15,15.2
ST   D21S11: 32.2 (PubMed=25230021)
ST   D21S11: 32.2,33.2 (ATCC; PubMed=22710073; PubMed=25877200; PubMed=30485824)
ST   D2S1338: 17,23
ST   D3S1358: 15,18
ST   D5S818: 11,13
ST   D7S820: 11
ST   D8S1179: 14
ST   FGA: 21
ST   Penta D: 8,13
ST   Penta E: 13,16
ST   TH01: 9.3
ST   TPOX: 8,12
ST   vWA: 16,17
DI   NCIt; C40078; Ovarian clear cell adenocarcinoma
DI   ORDO; Orphanet_398971; Clear cell adenocarcinoma of the ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   47Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 44
//
RX   DOI=10.26502/ogr072;
RA   Devor E.J., Lapierre J.R., Bender D.P.;
RT   "ES-2 ovarian cancer cells present a genomic profile inconsistent with
RT   their reported history.";
RL   Obstet. Gynecol. Res. 4:233-238(2021).
//
RX   PubMed=1717140;
RA   Lau D.H.M., Lewis A.D., Ehsan M.N., Sikic B.I.;
RT   "Multifactorial mechanisms associated with broad cross-resistance of
RT   ovarian carcinoma cells selected by cyanomorpholino doxorubicin.";
RL   Cancer Res. 51:5181-5187(1991).
//
RX   PubMed=9698466; DOI=10.1006/gyno.1998.5039;
RA   Maxwell G.L., Risinger J.I., Tong B., Shaw H., Barrett J.C.,
RA   Berchuck A., Futreal P.A.;
RT   "Mutation of the PTEN tumor suppressor gene is not a feature of
RT   ovarian cancers.";
RL   Gynecol. Oncol. 70:13-16(1998).
//
RX   PubMed=11103784;
RA   Hough C.D., Sherman-Baust C.A., Pizer E.S., Montz F.J., Im D.D.,
RA   Rosenshein N.B., Cho K.R., Riggins G.J., Morin P.J.;
RT   "Large-scale serial analysis of gene expression reveals genes
RT   differentially expressed in ovarian cancer.";
RL   Cancer Res. 60:6281-6287(2000).
//
RX   PubMed=12960427; DOI=10.1091/mbc.E03-05-0279;
RA   Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O.G.,
RA   Diehn M., Wang Y.C., Duran G.E., Sikic T.L., Caldeira S., Skomedal H.,
RA   Tu I.-P., Hernandez-Boussard T., Johnson S.W., O'Dwyer P.J., Fero M.J.,
RA   Kristensen G.B., Borresen-Dale A.-L., Hastie T., Tibshirani R.,
RA   van de Rijn M., Teng N.N.H., Longacre T.A., Botstein D., Brown P.O.,
RA   Sikic B.I.;
RT   "Gene expression patterns in ovarian carcinomas.";
RL   Mol. Biol. Cell 14:4376-4386(2003).
//
RX   PubMed=16382445; DOI=10.1002/gcc.20300;
RA   Wang Y.C., Juric D., Francisco B., Yu R.X., Duran G.E., Chen G.K.,
RA   Chen X., Sikic B.I.;
RT   "Regional activation of chromosomal arm 7q with and without gene
RT   amplification in taxane-selected human ovarian cancer cell lines.";
RL   Genes Chromosomes Cancer 45:365-374(2006).
//
RX   PubMed=17671176; DOI=10.1158/0008-5472.CAN-06-4567;
RA   Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K.,
RA   Hirohashi S., Inazawa J., Imoto I.;
RT   "Promoter hypermethylation contributes to frequent inactivation of a
RT   putative conditional tumor suppressor gene connective tissue growth
RT   factor in ovarian cancer.";
RL   Cancer Res. 67:7095-7105(2007).
//
RX   PubMed=18560578; DOI=10.1371/journal.pone.0002425;
RA   Faca V.M., Ventura A.P., Fitzgibbon M.P., Pereira-Faca S.R.,
RA   Pitteri S.J., Green A.E., Ireton R.C., Zhang Q., Wang H.,
RA   O'Briant K.C., Drescher C.W., Schummer M., McIntosh M.W.,
RA   Knudsen B.S., Hanash S.M.;
RT   "Proteomic analysis of ovarian cancer cells reveals dynamic processes
RT   of protein secretion and shedding of extra-cellular domains.";
RL   PLoS ONE 3:E2425-E2425(2008).
//
RX   PubMed=18720132; DOI=10.1080/10717540802329183;
RA   Serikawa T., Kikuchi H., Oite T., Tanaka K.;
RT   "Enhancement of gene expression efficiency using cationic liposomes on
RT   ovarian cancer cells.";
RL   Drug Deliv. 15:523-529(2008).
//
RX   PubMed=20081105; DOI=10.1210/me.2009-0295;
RA   Nagaraja A.K., Creighton C.J., Yu Z.-F., Zhu H.-F., Gunaratne P.H.,
RA   Reid J.G., Olokpa E., Itamochi H., Ueno N.T., Hawkins S.M.,
RA   Anderson M.L., Matzuk M.M.;
RT   "A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.";
RL   Mol. Endocrinol. 24:447-463(2010).
//
RX   PubMed=20204287; DOI=10.3892/or_00000728;
RA   Langland G.T., Yannone S.M., Langland R.A., Nakao A., Guan Y.-H.,
RA   Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.;
RT   "Radiosensitivity profiles from a panel of ovarian cancer cell lines
RT   exhibiting genetic alterations in p53 and disparate DNA-dependent
RT   protein kinase activities.";
RL   Oncol. Rep. 23:1021-1026(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22328975; DOI=10.1158/2159-8290.CD-11-0170;
RA   Hanrahan A.J., Schultz N., Westfal M.L., Sakr R.A., Giri D.D.,
RA   Scarperi S., Janakiraman M., Olvera N., Stevens E.V., She Q.-B.,
RA   Aghajanian C., King T.A., de Stanchina E., Spriggs D.R., Heguy A.,
RA   Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.;
RT   "Genomic complexity and AKT dependence in serous ovarian cancer.";
RL   Cancer Discov. 2:56-67(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22705003; DOI=10.1016/j.humpath.2012.03.011;
RA   Rahman M., Nakayama K., Rahman M.T., Nakayama N., Ishikawa M.,
RA   Katagiri A., Iida K., Nakayama S., Otsuki Y., Shih I.-M.,
RA   Miyazaki K.;
RT   "Clinicopathologic and biological analysis of PIK3CA mutation in
RT   ovarian clear cell carcinoma.";
RL   Hum. Pathol. 43:2197-2206(2012).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007;
RA   Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S.,
RA   Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G.,
RA   Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J.,
RA   Mills G.B., Hennessy B.T.;
RT   "BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one
RT   functionally deleterious BRCA1 mutation.";
RL   Mol. Oncol. 7:567-579(2013).
//
RX   PubMed=23839242; DOI=10.1038/ncomms3126;
RA   Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.;
RT   "Evaluating cell lines as tumour models by comparison of genomic
RT   profiles.";
RL   Nat. Commun. 4:2126.1-2126.10(2013).
//
RX   PubMed=24023729; DOI=10.1371/journal.pone.0072162;
RA   Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M.,
RA   Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R.,
RA   Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.;
RT   "Type-specific cell line models for type-specific ovarian cancer
RT   research.";
RL   PLoS ONE 8:E72162-E72162(2013).
//
RX   PubMed=25049276; DOI=10.1136/jclinpath-2014-202430;
RA   Kwok A.L.M., Wong O.G.-W., Wong E.S.Y., Tsun O.K.-L., Chan K.-K.,
RA   Cheung A.N.-Y.;
RT   "Caution over use of ES2 as a model of ovarian clear cell carcinoma.";
RL   J. Clin. Pathol. 67:921-922(2014).
//
RX   PubMed=25230021; DOI=10.1371/journal.pone.0103988;
RA   Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M.,
RA   Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J.,
RA   Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J.,
RA   Helleman J.;
RT   "Ovarian cancer cell line panel (OCCP): clinical importance of in
RT   vitro morphological subtypes.";
RL   PLoS ONE 9:E103988-E103988(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26388441; DOI=10.1016/j.cell.2015.08.056;
RA   Creixell P., Schoof E.M., Simpson C.D., Longden J., Miller C.J.,
RA   Lou H.J., Perryman L., Cox T.R., Zivanovic N., Palmeri A.,
RA   Wesolowska-Andersen A., Helmer-Citterich M., Ferkinghoff-Borg J.,
RA   Itamochi H., Bodenmiller B., Erler J.T., Turk B.E., Linding R.;
RT   "Kinome-wide decoding of network-attacking mutations rewiring cancer
RT   signaling.";
RL   Cell 163:202-217(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J.,
RA   Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A.,
RA   Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J.,
RA   Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.;
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//
RX   PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096;
RA   Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M.,
RA   Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R.,
RA   Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J.,
RA   Velculescu V.E., Scharpf R.B.;
RT   "Integrated genomic, epigenomic, and expression analyses of ovarian
RT   cancer cell lines.";
RL   Cell Rep. 25:2617-2633(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//